Flare Therapeutics
Updated: January 02, 2026
CEO Amit Rakhit
Country: USA | Funding: $205M (+)
Founded: 2021
Website: https://www.flaretx.com/
Flare Therapeutics develops personalized drugs based on transcription factors - DNA-binding proteins that can activate or repress DNA transcription and, therefore, control gene expression. As drug targets, TFs differ from many other classes of targets in that they determine the identity of cells and tissues, controlling which genes are expressed and which are not. The integrated FlareTx platform uses two complementary strategies to identify potential ligand-binding sites within transcription factors: site mapping and chemoproteomics. Flare Therapeutics' initial focus is precision oncology, with leading programs in advanced urothelial cancer and prostate cancer. Their small molecules are designed to restore transcriptional control disrupted by cancer.
Founded: 2021
Website: https://www.flaretx.com/
Flare Therapeutics develops personalized drugs based on transcription factors - DNA-binding proteins that can activate or repress DNA transcription and, therefore, control gene expression. As drug targets, TFs differ from many other classes of targets in that they determine the identity of cells and tissues, controlling which genes are expressed and which are not. The integrated FlareTx platform uses two complementary strategies to identify potential ligand-binding sites within transcription factors: site mapping and chemoproteomics. Flare Therapeutics' initial focus is precision oncology, with leading programs in advanced urothelial cancer and prostate cancer. Their small molecules are designed to restore transcriptional control disrupted by cancer.
